


CLAIMS


- ### 1. A compound of the formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein:

A and B independently represent CH₂ or O, with the proviso that A and B are not simultaneously O;

Cy represents one of the following



optionally substituted by one to three groups selected from hydroxy, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆haloalkyl, C₁₋₆alkylamino and amino;

R¹ and R² are independently selected from hydroxy, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆haloalkyl and C₃₋₈ cycloalkyl;

n represents an integer from 0-4;

X is hydrogen, hydroxy, halogen or C₁₋₆ alkoxy;

Y is oxy, thio, a 1-4 membered alkylene, a 2-4 membered alkylene ether, 2-4 membered alkylene thioether or an oxyethyleneoxy group, optionally substituted by 1 to 4 groups independently selected from hydroxy, halogen, C₁₋₆alkyl, C₁₋₆alkoxy and C₁₋₆haloalkyl;

Z is CH or N; and

p represents an integer from 0-5 when Z is CH or 0-4 when Z is N,

when p represents 2 or more, two of R²s may be taken together with the carbon atoms to which they are attached to form a 5-8 membered cycloalkyl ring.

2. A compound according to claim 1 where A and B represent carbon atoms.
3. A compound according to claim 1 where A represents O and B represents C.
4. A compound according to claim 1 where A represents C and B represents O.
5. A compound according to any one of claims 1 to 4 where Cy is selected from optionally further substituted 4-hydroxyphenyl, 1*H*-pyrazol-4-yl, 2-oxo-2,3-dihydro-1,3-benzoxazole-6-yl and 2-hydroxy-5-pyridyl.
6. A compound according to any one of claims 1 to 5 where Cy represents 4-hydroxyphenyl, optionally further substituted by fluoro or methyl.
7. A compound according to any one of claims 1 to 6 where n represents 0.
8. A compound according to any one of claims 1 to 7 where R² represents methoxy, chloro, fluoro or methyl.

9. A compound according to any one of claims 1 to 8 where p represents 0-2.
10. A compound according to any one of claims 1 to 9 where X is hydrogen or hydroxy.
11. A compound according to any one of claims 1 to 10 where Y is selected from methylene, oxyethyleneoxy, oxymethylene, methyleneoxy, methyleneoxymethylene, ethyleneoxy, oxyethylene and oxy.
12. A compound according to any one of claims 1 to 11 where Y is *para* located to and in a *trans* configuration to X.
13. A compound of formula (I) selected from:
4-Hydroxy-N-{{*cis*-4-(phenoxyethyl)cyclohexyl}methyl}benzamide;
4-Hydroxy-N-({*cis*-4-[{(4-methoxyphenoxy)methyl]cyclohexyl}methyl}benzamide;
N-{{*cis*-4-(Benzyoxy)cyclohexyl}methyl}-4-hydroxybenzamide;
N-({*cis*-4-[(4-Chlorobenzyl)oxy]cyclohexyl}methyl)-4-hydroxybenzamide;
N-({*cis*-4-[(3-Chlorobenzyl)oxy]cyclohexyl}methyl)-4-hydroxybenzamide;
4-Hydroxy-N-{{*cis*-4-(4-methoxyphenoxy)cyclohexyl}methyl}benzamide;
N-{{*cis*-4-(4-Chlorophenoxy)cyclohexyl}methyl}-4-hydroxybenzamide;
4-Hydroxy-N-{{[1-hydroxy-4-(phenoxyethyl)cyclohexyl]methyl}benzamide;
N-({*trans*-4-[(4-Fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[(3-Fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[(2-Fluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;
N-({*trans*-4-[(2,6-Difluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[{(3,5-Difluorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[{(3-Chlorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[{(4-Chlorophenoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

4-Hydroxy-*N*-({*trans*-1-hydroxy-4-[{(2-methylphenoxy)methyl]cyclohexyl}methyl)benzamide;

4-Hydroxy-*N*-({*trans*-1-hydroxy-4-[{(3-methylphenoxy)methyl]cyclohexyl}methyl)benzamide;

4-Hydroxy-*N*-({*trans*-1-hydroxy-4-[{(4-methylphenoxy)methyl]cyclohexyl}methyl)benzamide;

N-({*trans*-4-[{(Benzyoxy)methyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-[({*trans*-4-{[(2-Fluorobenzyl)oxy]methyl}-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;

N-[({*trans*-4-{[(4-Fluorobenzyl)oxy]methyl}-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;

4-Hydroxy-*N*-{[{*trans*-1-hydroxy-4-(2-phenoxyethyl)cyclohexyl}methyl]benzamide;

N-({*trans*-4-[2-(2-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[2-(3-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-({*trans*-4-[2-(4-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl}methyl)-4-hydroxybenzamide;

N-{[{*trans*-4-(Benzyoxy)-1-hydroxycyclohexyl}methyl]-4-hydroxybenzamide;

N-{[{*trans*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl}methyl]-4-hydroxybenzamide;

N-{[{*cis*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl}methyl]-4-hydroxybenzamide;

N-{[{*trans*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl}methyl]-3-fluoro-4-hydroxybenzamide;

N-{[{*cis*-4-(4-Chlorophenoxy)-1-hydroxycyclohexyl}methyl]-3-fluoro-4-hydroxybenzamide; (+)-4-hydroxy-*N*-{[{5*S*-(phenoxy)methyl)tetrahydro-2*H*-pyran-2*S*-yl}methyl]benzamide;

(-)4-hydroxy-N-{{[5R-(phenoxyethyl)tetrahydro-2H-pyran-2R-yl]methyl}benzamide;
4-hydroxy-N-{{[5S-(benzyloxymethyl)tetrahydro-2H-pyran-2S-yl]methyl}benzamide;
4-hydroxy-N-{{[5R-(benzyloxymethyl)tetrahydro-2H-pyran-2R-yl]methyl}benzamide;
(-)4-Hydroxy-N-{{[(3R,6S)-6-(phenoxyethyl)tetrahydro-2H-pyran-3-
yl]methyl}benzamide;
(+)-4-Hydroxy-N-{{[(3S,6R)-6-(phenoxyethyl)tetrahydro-2H-pyran-3-
yl]methyl}benzamide;
N-({trans}-4-[(2-Fluorobenzyl)oxy]-1-hydroxycyclohexyl)methyl)-4-hydroxybenzamide;
3-Fluoro-N-({trans}-4-[2-(2-fluorophenoxy)ethyl]-1-hydroxycyclohexyl)methyl)-4-
hydroxybenzamide;
trans-N-{{[4-(4-chlorophenoxy)cyclohexyl]methyl}-3-fluoro-4-hydroxybenzamide;
cis-N-{{[4-(4-chlorophenoxy)cyclohexyl]methyl}-3-fluoro-4-hydroxybenzamide;
N-{{*cis*-4-(4-Fluorophenoxy)cyclohexyl]methyl}-4-hydroxybenzamide;
3-Fluoro-N-{{*cis*-4-(4-fluorophenoxy)cyclohexyl]methyl}-4-hydroxybenzamide;
N-({trans}-4-[2-(2-Fluorophenoxy)ethyl]-1-hydroxycyclohexyl)methyl)-1*H*-pyrazole-4-
carboxamide;
4-hydroxy-N-{{*cis*-4-(2-phenylethoxy)cyclohexyl]methyl}benzamide;
2-fluoro-4-hydroxy-N-{{*trans*-1-hydroxy-4-(phenoxyethyl)cyclohexyl]methyl}benzamide;
N-({trans}-4-[(benzyloxy)methyl]-1-hydroxycyclohexyl)methyl)-3-fluoro-4-
hydroxybenzamide;
N-({*cis*-4-[(Benzyl)oxy]methyl)cyclohexyl)methyl)-4-hydroxybenzamide
3-Fluoro-4-hydroxy-N-{{*trans*-1-hydroxy-4-
(phenoxyethyl)cyclohexyl]methyl}benzamide;
3-Fluoro-4-hydroxy-N-{{*trans*-1-hydroxy-4-(2-
phenoxyethyl)cyclohexyl]methyl}benzamide;
3-Fluoro-N-[(*trans*-4-{{(4-fluorobenzyl)oxy}methyl}-1-hydroxycyclohexyl)methyl]-4-
hydroxybenzamide;
3-Fluoro-N-({*trans*-4-[(2-fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl}-4-
hydroxybenzamide;
3-Fluoro-N-({*trans*-4-[(4-fluorophenoxy)methyl]-1-hydroxycyclohexyl)methyl}-4-
hydroxybenzamide;

4-Hydroxy-*N*-[(*trans*-1-hydroxy-4-{[(5-methylpyridin-2-yl)oxy]methyl}cyclohexyl)methyl]benzamide;
N-[*(trans*-4-Benzyl-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
3-fluoro-*N*-[*(trans*-4-{[(2-fluorobenzyl)oxy]methyl}-1-hydroxycyclohexyl)methyl]-4-hydroxybenzamide;
6-Hydroxy-*N*-{[*cis*-4-(2-phenethoxy)cyclohexyl]methyl}nicotinamide;
N-{[*cis*-4-(2-Phenylethoxy)cyclohexyl]methyl}-1*H*-pyrazole-4-carboxamide;
N-{[*cis*-4-(Phenoxyethyl)cyclohexyl]methyl}-1*H*-pyrazole-4-carboxamide;
N-{[*cis*-4-(2-Phenoxyethyl)cyclohexyl]methyl}-1*H*-pyrazole-4-carboxamide;
N-{[*cis*-4-[(3-Fluorophenoxy)methyl]cyclohexyl]methyl}-1*H*-pyrazole-4-carboxamide;
N-{[*cis*-4-[(4-Fluorophenoxy)methyl]cyclohexyl]methyl}-1*H*-pyrazole-4-carboxamide;
N-{[(2*R*,5*R*)-5-[(4-Fluorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl]methyl}-1*H*-pyrazole-4-carboxamide;
N-{[*cis*-4-(4-Methoxybenzyl)cyclohexyl]methyl}-1*H*-pyrazole-4-carboxamide;
3-Amino-*N*-[*(cis*-4-benzylcyclohexyl)methyl]-1*H*-pyrazole-4-carboxamide;
N-{[(2*R*,5*R*)-5-[(4-Chlorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl]methyl}-1*H*-pyrazole-4-carboxamide;
3-Amino-*N*-{[(2*R*,5*R*)-5-[(4-fluorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl]methyl}-1*H*-pyrazole-4-carboxamide;
3-Amino-*N*-{[(2*R*,5*R*)-5-[(4-chlorophenoxy)methyl]tetrahydro-2*H*-pyran-2-yl]methyl}-1*H*-pyrazole-4-carboxamide; and
3-Amino-*N*-{[(2*R*,5*R*)-5-[(4-ethylphenoxy)methyl]tetrahydro-2*H*-pyran-2-yl]methyl}-1*H*-pyrazole-4-carboxamide;
or a pharmaceutically acceptable salt or solvate thereof.

14. A pharmaceutical composition including a compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of claims 1 to 13, together with a pharmaceutically acceptable excipient.

15. A compound of the formula (I) or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of claims 1 to 14, for use as a medicament.

16. The use of a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or composition thereof, as defined in any one of claims 1 to 13 and 14, respectively, for the manufacture of a medicament to treat a disease for which an NMDA NR2B antagonist is indicated.
17. A use according to claim 16 where the disease is selected from pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety and migraine.
18. A method of treatment of a mammal, including a human being, to treat a disease for which an NMDA NR2B antagonist is indicated, including treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof, as defined in any one of claims 1 to 13 and 14, respectively.
19. A method according to claim 18 where the disease is selected from pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety and migraine.
20. A combination of a compound of the formula (I), as defined in any one of claims 1-13, and another pharmacologically active agent.